Youngflex Manufacturing Inc.

Revolutionary Natural Youngflex Preventive Therapy has been successfully developed after thorough market research to fill in huge market gap and large number of chronic pain patients, who have longed for a safe and effective natural preventive therapy for chronic pains. Our team then undertook this grand mission in mid 1990s and has successfully developed unique natural Youngflex Preventive therapy after more than 50,000 cases of clinical testings , which comprises : (1) Brand new software - establish The Root Causes of deep tissue muscle pain for each chronic pain symptom that X-rays, MRIs or CTs cannot systematically locate; (2) Brand new hardware - invent a perfect match topical herbal remedy to safely and effectively remove such deep tissue muscle pain areas; (3) Brand new Application Methodology - Ensure all regenerative cells are in a state of motion to ensure that there is smooth blood circulation so that all nutrients in blood stream can smoothly flow into weak joints/spine, making them strong and all related muscle and soft tissues can regain strength to support body movements, thereby preventing damages to joints/spine and shrinking of muscles. Then carry out appropriate sets of osteopathic exercises to speed up recovery process; (4) Establish Regular Health Maintenance Program - in order to timely remove ROOT causes of deep tissue muscle inflammation as and when they occur due to continuous pressure and fatigue from challenging research and executive workloads before this type of chronic pain subhealth symptoms become more serious affecting joints/spine.

Our revolutionary natural Youngflex Preventive Therapy is in full compliance with China government's health strategy - to establish "Prevention better than Cure" health care system in order to improve the quality of life for people as well as the quality of GDP for the country.

Obtained an inventive copyright certificate issued by Canadian CIPO and 100% effectiveness clinical testing report done by Tianjin Chinese Medicine Hospital.

Just completed two-year promotion and market simulation testing searching niche market segment for developing initial Youngflex Preventive Therapy business in China. According to our records, we plan to initially develop 1%+ of the huge chronic pain market about 300 million patients in China, which is about 4 million targeting volume clientele base from large & medium technological enterprises in China . From our existing clientele base, we have noticed senior executives, who care for health, will be our initial target customers because they have shown top RR, excellent LTV and low CAC with prepay good cashflow. From our records, such clients spend RMB3000 - RMB5000 up per member per year. Therefore, such 4 million senior executives will generate conservatively RMB12,000,000,000 = RMB3,000/member/year x 4,000,000 members with net profit after tax about 35%+.

We plan to establish two model Youngflex Preventive Centers in GBA of China such as Shenzhen and Canton and our operation center for RMB5 million as angel investment, which equals to 10% of our shareholding to investors, who a have common goal, with volume elite resources from large and medium size technological companies in China such that high level executives and research personnel will be Youngflex members. And then expand to major cities in China. Before IPO, we will plan to roll out fully automatic AI Robotic Youngflex Preventive Centers with big data operations system to meet with fast expanding business model and then expand to viable overseas markets.